Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Interim Statements of Loss and Comprehensive Loss (Unaudited)

v3.24.1.1.u2
Condensed Consolidated Interim Statements of Loss and Comprehensive Loss (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Revenue $ 0 $ 0
Expenses:    
Research and development 6,445 8,811
General and administrative 3,315 5,285
Operating expenses 9,760 14,096
Other income/(expense):    
Interest income 121 422
Foreign exchange loss (1) (2)
Total other income 120 420
Net loss (9,640) (13,676)
Other comprehensive loss:    
Unrealized (loss) gain on available-for-sale securities (1) 4
Total comprehensive loss $ (9,641) $ (13,672)
Basic loss per common share (in dollars per share) $ (0.73) $ (2.22)
Diluted loss per common share (in dollars per share) $ (0.73) $ (2.22)
Weighted average number of common shares outstanding (in thousands) used in the calculation of basic loss per common share (in shares) 13,133 6,171
Weighted average number of common shares outstanding used in the calculation of diluted loss per common share ( in shares) 13,133 6,171